Investor's Business Daily on MSN3mon
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.Novocure stock advanced Wednesday morning — but pulled back from more massive gains — after the Food and Drug Administration ...
Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough.
From the beginning of 2024 through Dec. 3, shares of Novocure rose 112% higher. They've been soaring because, in addition to positive pancreatic cancer results, its Optune Lua device earned ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback